{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:33:45Z","timestamp":1793295225564,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z181100001918019"],"award-info":[{"award-number":["Z181100001918019"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7202025"],"award-info":[{"award-number":["7202025"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7202026"],"award-info":[{"award-number":["7202026"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700197"],"award-info":[{"award-number":["81700197"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32300655"],"award-info":[{"award-number":["32300655"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300214"],"award-info":[{"award-number":["82300214"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070205"],"award-info":[{"award-number":["82070205"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970179"],"award-info":[{"award-number":["81970179"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670187"],"award-info":[{"award-number":["81670187"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972807"],"award-info":[{"award-number":["81972807"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870154"],"award-info":[{"award-number":["81870154"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.canlet.2024.216996","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T02:22:11Z","timestamp":1716949331000},"page":"216996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4\/6 inhibitor palbociclib via PLK1 in B-cell lymphoma"],"prefix":"10.1016","volume":"597","author":[{"given":"Dingyao","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaowu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3479-2547","authenticated-orcid":false,"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.216996_bib1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev-immunol-020711-075027","article-title":"Pathogenesis of human B cell lymphomas","volume":"30","author":"Shaffer","year":"2012","journal-title":"Annu. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.canlet.2024.216996_bib2","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1002\/cam4.3037","article-title":"Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.canlet.2024.216996_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-019-0785-7","article-title":"Burden of lymphoma in China, 2006-2016: an analysis of the global burden of disease study 2016","volume":"12","author":"Liu","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2024.216996_bib4","first-page":"209","article-title":"Global cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.canlet.2024.216996_bib5","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1016\/S1470-2045(13)70450-9","article-title":"Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines","volume":"14","author":"Tan","year":"2013","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.canlet.2024.216996_bib6","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN Guidelines\u00ae insights: B-cell lymphomas, version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.canlet.2024.216996_bib7","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1182\/blood-2002-07-2009","article-title":"Cell cycle deregulation in B-cell lymphomas","volume":"101","author":"S\u00e1nchez-Beato","year":"2003","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.canlet.2024.216996_bib8","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","article-title":"Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways","volume":"23","author":"Fern\u00e0ndez","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.canlet.2024.216996_bib9","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.2016.69.0032","article-title":"Cell-cycle therapeutics come of age","volume":"35","author":"Ingham","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2024.216996_bib10","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/bjc.2017.92","article-title":"Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies","volume":"116","author":"Bahleda","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.canlet.2024.216996_bib11","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","article-title":"A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma","volume":"133","author":"Martin","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216996_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215775","article-title":"Kinase inhibitors for precision therapy of triple-negative breast cancer: progress, challenges, and new perspectives on targeting this heterogeneous disease","volume":"547","author":"Mehlich","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216996_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215665","article-title":"Palbociclib in combination with sunitinib exerts a synergistic anti-cancer effect in patient-derived xenograft models of various human cancers types","volume":"536","author":"Moskovits","year":"2022","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.canlet.2024.216996_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100628","article-title":"The hyperproliferation mechanism of cholesteatoma based on proteomics: SNCA promotes autophagy-mediated cell proliferation through the PI3K\/AKT\/CyclinD1 signaling pathway","volume":"22","author":"Gao","year":"2023","journal-title":"Mol. Cell. Proteomics"},{"issue":"2","key":"10.1016\/j.canlet.2024.216996_bib15","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1128\/MCB.19.2.1346","article-title":"Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts","volume":"19","author":"Takuwa","year":"1999","journal-title":"Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.canlet.2024.216996_bib16","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/cdd.2015.23","article-title":"Notch signaling in response to excitotoxicity induces neurodegeneration via erroneous cell cycle reentry","volume":"22","author":"Marathe","year":"2015","journal-title":"Cell Death Differ."},{"issue":"6","key":"10.1016\/j.canlet.2024.216996_bib17","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/hep.25596","article-title":"Cyclin G1-mediated epithelial-mesenchymal transition via phosphoinositide 3-kinase\/Akt signaling facilitates liver cancer progression","volume":"55","author":"Wen","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.canlet.2024.216996_bib18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-021-01140-z","article-title":"Phase 1 clinical trial of the PI3K\u03b4 inhibitor YY-20394 in patients with B-cell hematological malignancies","volume":"14","author":"Jiang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2024.216996_bib19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"13","key":"10.1016\/j.canlet.2024.216996_bib20","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood.2020006784","article-title":"Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma","volume":"138","author":"Xu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216996_bib21","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/ncomms2879","article-title":"PI 3-kinase-dependent phosphorylation of Plk1-Ser99 promotes association with 14-3-3\u03b3 and is required for metaphase-anaphase transition","volume":"4","author":"Kasahara","year":"2013","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.canlet.2024.216996_bib22","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.bbrc.2018.12.182","article-title":"Insulin promotes proliferation of pancreatic ductal epithelial cells by increasing expression of PLK1 through PI3K\/AKT and NF-\u03baB pathway","volume":"509","author":"Wu","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"21","key":"10.1016\/j.canlet.2024.216996_bib23","doi-asserted-by":"crossref","first-page":"6813","DOI":"10.1158\/1078-0432.CCR-08-0626","article-title":"Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma","volume":"14","author":"Wang","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2024.216996_bib24","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1186\/s12885-017-3884-2","article-title":"Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer","volume":"17","author":"Zhang","year":"2017","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.canlet.2024.216996_bib25","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/cdd.2013.5","article-title":"CDC25A targeting by miR-483-3p decreases CCND-CDK4\/6 assembly and contributes to cell cycle arrest","volume":"20","author":"Bertero","year":"2013","journal-title":"Cell Death Differ."},{"issue":"6631","key":"10.1016\/j.canlet.2024.216996_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/387417a0","article-title":"Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15","volume":"387","author":"Iavarone","year":"1997","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.canlet.2024.216996_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.canlet.2024.216996_bib28","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.canlet.2024.216996_bib29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy","volume":"37","author":"Sha","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2024.216996_bib30","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1002\/imt2.36","article-title":"Sangerbox: a comprehensive, interaction-friendly clinical bioinformatics analysis platform","volume":"1","author":"Shen","year":"2022","journal-title":"iMeta"},{"issue":"1","key":"10.1016\/j.canlet.2024.216996_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.canlet.2024.216996_bib32","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/hon.3009","article-title":"Anti-CD47 immunotherapy in combination with BCL-2 inhibitor to enhance anti-tumor activity in B-cell lymphoma","volume":"40","author":"Li","year":"2022","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216996_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215800","article-title":"Early functional mismatch between breast cancer cells and their tumour microenvironment suppresses long term growth","volume":"544","author":"Perdrix Rosell","year":"2022","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.canlet.2024.216996_bib34","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.canlet.2024.216996_bib35","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.omto.2021.03.015","article-title":"Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma","volume":"21","author":"Yu","year":"2021","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"10.1016\/j.canlet.2024.216996_bib36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ijc.31044","article-title":"The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma","volume":"142","author":"Li","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2024.216996_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.85","article-title":"OmicStudio: a composable bioinformatics cloud platform with real-time feedback that can generate high-quality graphs for publication","volume":"2","author":"Lyu","year":"2023","journal-title":"iMeta"},{"issue":"5","key":"10.1016\/j.canlet.2024.216996_bib38","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.canlet.2024.216996_bib39","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"491","key":"10.1016\/j.canlet.2024.216996_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.canlet.2024.216996_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153283","article-title":"Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma","volume":"132","author":"Yi","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2024.216996_bib42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf."},{"issue":"7","key":"10.1016\/j.canlet.2024.216996_bib43","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1158\/2159-8290.CD-11-0249","article-title":"PI3K\u03b4 inhibitors in cancer: rationale and serendipity merge in the clinic","volume":"1","author":"Fruman","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216996_bib44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2021.12.021","article-title":"AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK\/PI3K-AKT pathway","volume":"528","author":"Liu","year":"2022","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.canlet.2024.216996_bib45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc1841","article-title":"Targeting polo-like kinase 1 for cancer therapy","volume":"6","author":"Strebhardt","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.canlet.2024.216996_bib46","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrd3184","article-title":"Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy","volume":"9","author":"Strebhardt","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2024.216996_bib47","article-title":"CDK6 immunophenotype implicates potential therapeutic application of CDK4\/6 inhibitors in urothelial carcinoma","volume":"12","author":"Sun","year":"2022","journal-title":"Front. Oncol."},{"issue":"16","key":"10.1016\/j.canlet.2024.216996_bib48","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1158\/0008-5472.CAN-21-0590","article-title":"CDK6 is a therapeutic target in myelofibrosis","volume":"81","author":"Dutta","year":"2021","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.canlet.2024.216996_bib49","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.canlet.2024.216996_bib50","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clml.2015.02.021","article-title":"A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma","volume":"15","author":"Cassaday","year":"2015","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"issue":"3","key":"10.1016\/j.canlet.2024.216996_bib51","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3324\/haematol.2019.224535","article-title":"Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study","volume":"106","author":"Morschhauser","year":"2021","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.canlet.2024.216996_bib52","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/cc.24928","article-title":"Induction of prolonged early G1 arrest by CDK4\/CDK6 inhibition reprograms lymphoma cells for durable PI3K\u03b4 inhibition through PIK3IP1","volume":"12","author":"Chiron","year":"2013","journal-title":"Cell Cycle"},{"issue":"9","key":"10.1016\/j.canlet.2024.216996_bib53","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.canlet.2024.216996_bib54","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canlet.2024.216996_bib55","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/blood-2016-08-731240","article-title":"Silencing c-Myc translation as a therapeutic strategy through targeting PI3K\u03b4 and CK1\u03b5 in hematological malignancies","volume":"129","author":"Deng","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.canlet.2024.216996_bib56","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2009-06-222943","article-title":"PI3K\/p110{delta} is a novel therapeutic target in multiple myeloma","volume":"116","author":"Ikeda","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.canlet.2024.216996_bib57","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.canlet.2024.216996_bib58","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/hon.3164_414","article-title":"Prolonged cell cycle arrest by the CDK4\/6 antagonist narazaciclib restores ibrutinib response in preclinical models of BTKi-resistant mantle cell lymphoma","volume":"41","author":"Profit\u00f3s-Pelej\u00e0","year":"2023","journal-title":"Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2024.216996_bib59","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41419-019-2158-0","article-title":"Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K\/AKT activation in B-cell lymphoid malignancies","volume":"10","author":"Kapoor","year":"2019","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.canlet.2024.216996_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171221","article-title":"PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO\/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors","volume":"12","author":"Yahiaoui","year":"2017","journal-title":"PLoS One"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524003902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524003902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:55:02Z","timestamp":1778684102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524003902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":60,"alternative-id":["S0304383524003902"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216996","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4\/6 inhibitor palbociclib via PLK1 in B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216996"}}